[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634370":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":77,"collaborators":19,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":19,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":19,"enrollmentInfo":88,"targetDuration":19,"studyType":91,"phases":92,"briefSummary":95,"conditions":96,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Avistone Biotechnology Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ANS02","EXPERIMENTAL","ANS02 capsules, oral administration",[13],"Drug: ANS02",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","4 dose levels would be explored during the study.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Avistone Clinical Study Information Center","CONTACT","8610 84148921","information.center@avistonebio.com",[27,41,52,60,68],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"Research Site","RECRUITING","Fairfax","Virginia","22031","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-77.30637,38.84622,{"lat":39,"lon":38},{"facility":28,"status":42,"city":43,"state":44,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":51,"contacts":19},"NOT_YET_RECRUITING","Guangzhou","Guangdong","China","CN",{"type":36,"coordinates":48},[49,50],113.25,23.11667,{"lat":50,"lon":49},{"facility":28,"status":29,"city":53,"state":54,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":55,"geoPoint":59,"contacts":19},"Harbin","Heilongjiang",{"type":36,"coordinates":56},[57,58],126.65,45.75,{"lat":58,"lon":57},{"facility":28,"status":42,"city":61,"state":62,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":19},"Zhengzhou","Henan",{"type":36,"coordinates":64},[65,66],113.64861,34.75778,{"lat":66,"lon":65},{"facility":69,"status":42,"city":70,"state":71,"zip":19,"country":45,"countryCode":46,"cosmosGeoPoint":72,"geoPoint":76,"contacts":19},"Study Site","Chengdu","Sichuan",{"type":36,"coordinates":73},[74,75],104.06667,30.66667,{"lat":75,"lon":74},{"type":78,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100634370","phase-1-a-study-to-investigate-ans02-in-participants-with-egfr-mutation-positive-non-small-cell-lung-cancer-100634370",false,"NCT07538804","A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","A Phase I\u002FII, Open-Label, Multicenter Study to Evaluate the Safety\u002FTolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Life expectancy ≥ 12 weeks\n* Measurable disease per RECIST v1.1\n* Adequate organ and marrow function as defined in the protocol\n* With documentation of EGFR alteration\n\nExclusion Criteria:\n\n* Active infection including tuberculosis and HBV, HCV or HIV\n* Known active or untreated CNS metastases\n* Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression\n* Participants with serious cardiovascular or cerebrovascular diseases","ALL","18 Years",{"count":89,"type":90},294,"ESTIMATED","INTERVENTIONAL",[93,94],"PHASE1","PHASE2","This is a first-in-human (FIH) Phase I\u002FII, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.",[97],"Non-Small Cell Lung Cancer","2026-07-02",{"date":100,"type":101},"2026-07-06","ACTUAL",{"date":103,"type":90},"2026-07-10",{"date":105,"type":90},"2029-10-30",{"name":5,"class":6},5]